论文部分内容阅读
目的:检测结直肠癌患者外周血中上皮性骨架蛋白CK19 mRNA,分析比较其与不同临床病理指标之间的关系,探讨其对临床术后治疗的指导意义。方法:应用RT-PCR方法,选择特异性CK19 mRNA引物,避开假基因CK19b的干扰,检测39例结直肠癌患者外周血中上皮性骨架蛋白CK19 mRNA。用DNA直接测序法排除假基因CK19a的可能。结果:39例外周血CK19 mRNA总检出率为79.5％(31/39),Dukes C、D期(16/16,100.0％)高于Dukes A、B期(15/23,65.2％)(P<0.05)。有淋巴结转移者外周血CK19 mRNA均阳性(16/16),明显高于无淋巴结转移者(65.2％,P<0.05)。而外周血CK19 mRNA的表达与其他临床病理指标无相关性。结论:各期结直肠癌患者外周血均有较高CK19 mRNA表达,随病期进展,阳性率更高。
Objective: To detect the expression of epithelial scaffold protein CK19 mRNA in peripheral blood of patients with colorectal cancer, and analyze its relationship with different clinicopathological parameters, and to explore its guiding significance for clinical postoperative treatment. Methods: RT-PCR method was used to select the specific CK19 mRNA primers to avoid the CK19b pseudogenes and to detect the expression of CK19 mRNA in peripheral blood of 39 colorectal cancer patients. The direct DNA sequencing excludes the possibility of CK19a. Results: The total positive rate of CK19 mRNA in peripheral blood was 79.5% (31/39) in 39 cases, and higher in Dukes C and D (16/16, 100.0%) than in Dukes A and B (15/23 and 65.2%, P < 0.05). CK19 mRNA in peripheral blood with lymph node metastasis was positive (16/16), which was significantly higher than those without lymph node metastasis (65.2%, P <0.05). The expression of CK19 mRNA in peripheral blood had no correlation with other clinicopathological parameters. Conclusion: The expression of CK19 mRNA in peripheral blood of patients with colorectal cancer has a higher positive rate with the progression of the disease.